OUR THERAPEUTIC AREAS
To discover new treatments that improve patients’ lives, Servier invests an average of 20% of its sales revenue (excl. generic medicines) in R&D. The Group focuses its research and development efforts in therapeutic areas where needs are substantial.
CARDIOMETABOLISM
Cardiovascular diseases are the leading cause of mortality in the world. Committed for more than 60 years to the treatment of these pathologies, Servier has acquired renowned expertise. Servier has also been committed for many years to fighting diabetes, a complex and progressive disease that affects 422 million people world. This group will focus on Life Cycle Management (LCM) to capitalize on its medicines and expertise in incremental innovation, in particular by developing Single Pill Combinations (SPC). By simplifying treatment, these SPCs increase treatment compliance treatment of these pathologies, Servier has acquired recognized expertise.
ADD INDIAN DATA EPIDEMIOLOGY PREVALENCE OF CVD disease 2021/22 one line
NEUROSCIENCE
Immune-inflammatory diseases, or simply autoimmune diseases, refer to many conditions that are triggered or characterized by an inadequate immune-system response. Most of the time, these diseases have high frequency, severity and no curative treatments exist.
Our research aims to discover innovative medicines for 3 diseases that are very disabling for patients and have a major impact on public health: systemic lupus erythematosus, of which 10% are severe and do not respond to any treatment; Systemic scleroderma, which affects about 30,000 patients in Europe, and Sjögren’s disease, the second most frequent autoimmune disease after rheumatoid arthritis which affects approximately 189,000 patients in Europe.
These pathologies are the subject of intense fundamental clinical research and we have developed partnerships with academic teams and internationally renowned biotech companies to discover and develop new drugs capable of acting on the immune system. For example, research programs are underway in systemic lupus erythematosus with ILTOO Pharma and in Sjögren’s disease with OSE Immunotherapeutics.
ONCOLOGY
The number of patients affected by cancer is steadily on the rise. From now until 2032, the number of new cases per year is expected to double, reaching beyond 22 million. Cancer has become a key focus of therapeutic research for our Group and is now a top priority, as proven by the acquisition of Shire’s oncology branch in 2018.
Our R&D programs are exploring two tracks: therapies aimed at the restoration of programmed cell death (apoptosis) in cancer cells, and mobilizing the immune system (immuno-oncology).
Innovation in oncology also relies on close collaboration between industrial and academic partners involved in the research and development of new anticancer treatments. Servier has entered into numerous partnerships with academic institutions as well as with industrial partners and/or biotechnology companies.
